Poniard Financial Statements From 2010 to 2026
| PARD Stock | USD 0.0001 0.00 0.00% |
Check Poniard Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poniard Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Poniard financial statements analysis is a perfect complement when working with Poniard Pharmaceuticals Valuation or Volatility modules.
Poniard |
Poniard Pharmaceuticals Company Return On Equity Analysis
Poniard Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Poniard Pharmaceuticals Return On Equity | -2.1 |
Most of Poniard Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poniard Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Poniard Pharmaceuticals has a Return On Equity of -2.1037. This is 91.22% lower than that of the Biotechnology sector and 94.23% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Poniard Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Poniard Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Poniard Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Poniard Pharmaceuticals competition to find correlations between indicators driving Poniard Pharmaceuticals's intrinsic value. More Info.Poniard Pharmaceuticals is regarded third in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Poniard Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Poniard Pharmaceuticals Financial Statements
Poniard Pharmaceuticals stakeholders use historical fundamental indicators, such as Poniard Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Poniard Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Poniard Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Poniard Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Poniard Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington. PONIARD PHARMACEUT operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 7 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Other Information on Investing in Poniard Pink Sheet
Poniard Pharmaceuticals financial ratios help investors to determine whether Poniard Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Poniard with respect to the benefits of owning Poniard Pharmaceuticals security.